<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=2025632344154429&amp;ev=PageView&amp;noscript=1">

TKS 1 Investor Day 2019

Together, building the future of health.
25.1.19 @ 8.30AM-4PM
Four Seasons Hotel, Singapore

About TKS 1

TKS 1 is an early stage Venture fund investing in digital healthcare companies set up by SPRIM Ventures and Tikehau Capital.

This unique partnership combines SPRIM’s domain expertise and experience in the healthcare industry with Tikehau’s financial engineering capability and strength.

As the healthcare and life sciences industry is on the verge of radical transformation with the application of new technology and the use of artificial intelligence, TKS 1 seeks to capture exciting opportunities in this evolving space as it focuses on two core themes: digitalization and artificial intelligence.

VIEW THE PRESS RELEASE


Our 2017 Highlight

 

The Speakers

Speaker Image
Dr. Michael Shleifer
Co-Founder & Managing Partner, SPRIM
Speaker Image
Ivan Jarry
Co-Founder & Managing Partner, SPRIM
Speaker Image
Laurent Benissan
SPRIM Business Partner, SPRIM Ventures
Speaker Image
bruno de pampelonne
Chairman, Tikehau Investment Management
Speaker Image
Bryan Silverman
CEO, ObvioHealth
Speaker Image
Brett Giffin
CEO, Fibronostics
Speaker Image
Nicolas Durand
CEO, RegASK
Speaker Image
Dr. Mahmood Ahmed
CSO, Biotech Ventures

Agenda

08:30
-
09:00
Visitor registration
09:00
-
09:30
Introductory remarks
Welcome address by Dr. Michael Shleifer and Bruno de Pampelonne
09:30
-
10:00
ObvioHealth presentation
ObvioHealth commercializes software solutions to help healthcare industry players substantiate health claims. ObvioHealth’s proprietary digital platform, ClaimIt, utilizes a mobile app interface to execute clinical trials. It removes the costly overhead of physical site visits and brings clinical trials directly to the mobile device of each subject.
10:00
-
10:30
Fibronostics presentation
Fibronostics is a discovery platform developing non-invasive, algorithm-based diagnostics to improve treatment outcomes, facilitate screening of specific diseases and help prognosis in various chronic conditions. Fibronostics currently focuses on liver disease, identifying high-risk patients and early detection through two products, LiverFast Select and LiverFast.
10:30
-
11:00
Coffee break
11:00
-
11:30
RegASK presentation
RegAsk is a digital platform using Artificial Intelligence for answering regulatory questions about path-to-market and path-to-claims for product expansions into foreign markets. RegAsk is backed by a team of regulatory experts with a global perspective and years of navigating some of the most complicated regulatory hurdles in markets big and small.
11:30
-
12:00
Travecta presentation
Travecta Therapeutics develops novel chemistry for delivery of therapies to the brain. Travecta leverages a discovery platform to identify, simplify and categorize small molecules for enabling their transport across the blood-brain barrier. Travecta is based on the research of Professor David Silver at Duke-NUS.
12:00
-
12:30
Vanteres presentation
Vanteres is an innovative biotech company committed to the science-based development of lipid nutraceuticals for improving human health. Vanteres leverages its biomedical research expertise to develop actively transported lysophospholipids (ATLs) for a wide range of disease states. The company’s lead ATL is a lysophosphatidylcholine containing essential omega-3 fatty acids or Active-DHA. Active-DHA plays a critical role in the health and maintenance of multiple organs including brain, eye, and liver.
12:30
-
13:45
Lunch break
13:45
-
16:00
Roundtable & networking session

Contact Us Today - Learn more about our Ventures

Our Ventures

ObvioHealth-Logo-White.png
Fibronostics Logo H white.png
RegASK Logo white.png
Travecta-logo-white-complete.png
Vanteres-Logo-White-Trans.png